LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "patritumab deruxtecan" as a keyword



Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Pharmacology"

DOI: 10.1002/jcph.2137

Abstract: Patritumab deruxtecan is an antibody–drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide‐based cleavable linker. As part… read more here.

Keywords: clearance; patritumab deruxtecan; dxd; population pharmacokinetics ... See more keywords

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Sign Up to like & get
recommendations! Published in 2025 at "Nature Medicine"

DOI: 10.1038/s41591-025-03744-1

Abstract: Leptomeningeal metastatic disease (LMD) is a severe complication of solid cancers with poor outcomes and limited treatment options. The antibody–drug conjugate patritumab deruxtecan (HER3-DXd) demonstrated efficacy in breast and lung cancers, and HER3 is involved… read more here.

Keywords: leptomeningeal metastatic; trial; metastatic disease; patritumab deruxtecan ... See more keywords

Patritumab deruxtecan induces immunogenic cell death.

Sign Up to like & get
recommendations! Published in 2025 at "Oncoimmunology"

DOI: 10.1080/2162402x.2025.2514050

Abstract: ABSTRACT Antibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic payload to cancer cells. Here, we characterized the mode of action of the ADC patritumab deruxtecan, which is a monoclonal antibody specific for Erb-B2 Receptor Tyrosine… read more here.

Keywords: cell death; patritumab; immunogenic cell; patritumab deruxtecan ... See more keywords

Abstract A054: Evaluation of HER3-targeting ADC patritumab deruxtecan in irinotecan-resistant colorectal cancer PDX models reveals resistance mechanisms and informs rational combination strategies

Sign Up to like & get
recommendations! Published in 2025 at "Molecular Cancer Therapeutics"

DOI: 10.1158/1535-7163.targ-25-a054

Abstract: HER3 (ERBB3), a member of the EGFR family, activates PI3K/AKT signaling through dimerization with other ERBB receptors and is frequently implicated in resistance to targeted therapies. Patritumab deruxtecan (HER3-DXd), a HER3-directed antibody–drug conjugate (ADC), has… read more here.

Keywords: colorectal cancer; cancer; patritumab deruxtecan; combination strategies ... See more keywords

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.

Sign Up to like & get
recommendations! Published in 2022 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-21-1429

Abstract: HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne… read more here.

Keywords: patritumab deruxtecan; egfr tki; deruxtecan paving; tki resistant ... See more keywords